Tonix Pharmaceuticals Announces New Board Member, James Treco

Tonix Pharmaceuticals Holding Corp. 8-K

Pharmaceuticals Announces New Board Member, James Treco

YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced

the appointment of James Treco to its Board of Directors, effective immediately. Mr. Treco assumes the seat held by Charles Mather,

who has stepped down from the position of company director that he has held since 2011.

Lederman, M.D., President and Chief Executive Officer of Tonix commented, "We are pleased to welcome Mr. Treco to the Tonix

Board. With his deep expertise in corporate strategy and his financial leadership experience, we welcome the valuable insights

and guidance James will bring to Tonix."

am delighted to join the board of this innovative company and I look forward to working with the talented team at Tonix at this

exciting time in the Company's growth," said Mr. Treco.

has been my pleasure to have worked with the board and management team of Tonix these past eight years," said Mr. Mather.

"I wish the team all the best as they continue their important work addressing unmet needs and under-served populations."

Lederman commented, "We are grateful for Mr. Mather's long service and multiple contributions. On behalf of the Board

and management, I would like to thank Mr. Mather for his many contributions and dedicated service to Tonix. I wish him continued

success in his future endeavors."

Treco is a Managing Partner at First Chicago Advisors, Inc., a boutique financial advisory firm where he advises executives and

boards of directors of a wide range of companies, from global, large-cap companies to emerging companies. During his career he

has worked with various biotechnology companies. For the past decade, he has been involved with start-up companies affiliated

with Dartmouth Hitchcock Medical Center in Hanover, NH developing intellectual properties, a number of which have been sold and

licensed to larger, publicly-traded pharmaceutical companies. Prior to joining First Chicago Advisors, Mr. Treco was an investment

banker with Gleacher & Company that previously operated an investment banking business, providing corporate and institutional

clients with strategic and financial advisory services. Mr. Treco held various positions of increasing responsibility at Salomon

Brothers/Citigroup, where he used his extensive experience in the global capital markets to advise a wide range of clients. Mr.

Treco earned a B.A. from Yale University and an M.B.A. from the Stanford University Graduate School of Business.

Tonix Pharmaceuticals Holding Corp.

is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric

conditions and biological products to improve biodefense through potential medical counter-measures. Tonix is developing Tonmya *,

which is in Phase 3 development and has been granted Breakthrough Therapy designation by the FDA, as a bedtime treatment for PTSD.

Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer's disease under a separate IND to

support a Phase 2, potential pivotal, efficacy study and has been designated a Fast Track development program by the FDA for this

indication. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but by a unique mechanism

and designed for daytime dosing. Phase 1 clinical study of TNX-601 in healthy volunteers will be conducted outside of the U.S.

in 2019. Tonix's lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic

version of horsepox virus, currently in the pre-IND application stage.

has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL (cyclobenzaprine

HCl sublingual tablets) for the treatment of PTSD. TNX-102 SL is an investigational new drug and has not been approved for any

press release and further information about Tonix can be found at www.tonixpharma.com.

statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

These statements may be identified by the use of forward-looking words such as "anticipate," "believe,"

"forecast," "estimate," "expect," and "intend," among others. These forward-looking

statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors

that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include,

but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations;

our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party

payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization

of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read

the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the Securities

and Exchange Commission (the "SEC") on March 9, 2018, and periodic reports filed with the SEC on or after the date

thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

The information set forth herein speaks only as of the date thereof.